At the heart of Mironid’s innovation is our mission to transform the treatment landscape for patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases through novel scientific approaches.
Our Focus
WHAT MAKE US DIFFERENT?
Our Science
Mironid is a clinical stage company currently building and progressing a pipeline of drug development programmes that are targeted at cAMP degrading phosphodiesterase enzymes. The goal is to generate novel and differentiated therapies for a range of diseases with high unmet medical need.
See what we're developing
Our People
Mironid is a vibrant, growing, patient focused company led by an experienced team, driven to deliver innovative therapeutics for patients with ADPKD and other rare diseases where there exists a clear unmet clinical need.
Meet Us
NEWS
November 12, 2026
Mironid strengthens Board and clinical team to support next phase of growth
Glasgow, Scotland, November 12, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces the appointment of Dr. Omar Khwaja as Non-Executive Director of the Board. The Company has also strengthened its clinical team, supporting the advancement of […]
Read more de Mironid strengthens Board and clinical team to support next phase of growth
October 1, 2026
Mironid successfully doses initial cohorts in Phase 1 clinical trial investigating the Company’s first-in-class LoAc® small molecule for patients with ADPKD
Glasgow, Scotland, October 1, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has successfully dosed the initial cohorts in its Phase 1 clinical trial of its first-in-class LoAc® small molecule, marking Mironid’s transition to a […]
August 5, 2026
Mironid raises $46 million in Series B financing to advance clinical development of its treatment for rare kidney disease
Glasgow, Scotland, August 5, 2026 – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces it has raised $46 million in a Series B funding round. Neil Wilkie, CEO of Mironid said: “ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the […]